MCRB – seres therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Seres Therapeutics (MCRB) had its "buy" rating reaffirmed by Canaccord Genuity Group Inc.. They now have a $22.00 price target on the stock.
Seres Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
Microbiome Market Competitive Landscape Report 2026: Comprehensive Insights About 140+ Companies and 180+ Drugs [Yahoo! Finance]
Seres Therapeutics appoints Richard Kender as interim CEO [Seeking Alpha]
Seres Therapeutics Announces Appointment of Richard N. Kender as Executive Chair and Interim CEO; Provides Business Updates [Yahoo! Finance]
Form 10-K Seres Therapeutics, Inc. For: Dec 31
Form 8-K Seres Therapeutics, Inc. For: Mar 12
Form 4 Seres Therapeutics, Inc. For: Mar 04 Filed by: Brady Kelly
Form 3 Seres Therapeutics, Inc. For: Mar 02 Filed by: Brady Kelly
Form 4 Seres Therapeutics, Inc. For: Mar 04 Filed by: Kender Richard N
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.